The smaller reduction in cancer cell population of doxorubicin-resistant cells during doxorubicin administration means fewer necrotic cells are produced in the process, and accordingly a lower level of dendritic cells (Figure 5A), as necrotic cells indirectly promote dendritic cell maturation through the release of HMGB1. The gene discussed is HMGB1; the disease is cancer.